BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belmonte C, Ochoa D, Román M, Saiz-rodríguez M, Wojnicz A, Gómez-sánchez CI, Martín-vílchez S, Abad-santos F. Influence of CYP2D6 , CYP3A4 , CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol 2018;122:596-605. [DOI: 10.1111/bcpt.12960] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Tasaki M, Yasui-Furukori N, Kubo K, Yokoyama S, Shinozaki M, Sugawara N, Inoue Y, Shimoda K. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia. Ther Drug Monit 2021;43:589-92. [PMID: 33235024 DOI: 10.1097/FTD.0000000000000843] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Jallaq SA, Verba M, Strawn JR, Martin LJ, DelBello MP, Ramsey LB. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. J Child Adolesc Psychopharmacol 2021;31:56-62. [PMID: 32845723 DOI: 10.1089/cap.2020.0058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bechtold B, Clarke J. Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. Expert Opin Drug Metab Toxicol 2021;17:397-412. [PMID: 33339463 DOI: 10.1080/17425255.2021.1867105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Saiz-Rodríguez M, Almenara S, Navares-Gómez M, Ochoa D, Román M, Zubiaur P, Koller D, Santos M, Mejía G, Borobia AM, Rodríguez-Antona C, Abad-Santos F. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines 2020;8:E94. [PMID: 32331352 DOI: 10.3390/biomedicines8040094] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
5 Saiz-Rodríguez M, Valdez-Acosta S, Borobia AM, Burgueño M, Gálvez-Múgica MÁ, Acero J, Cabaleiro T, Muñoz-Guerra MF, Puerro M, Llanos L, Martínez-Pérez D, Ochoa D, Carcas AJ, Abad-Santos F. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. Clin Ther 2021;43:e86-e102. [PMID: 33812699 DOI: 10.1016/j.clinthera.2021.03.005] [Reference Citation Analysis]
6 Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev 2020;52:1-18. [PMID: 32008418 DOI: 10.1080/03602532.2020.1717517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Zubiaur P, Saiz-Rodríguez M, Ochoa D, Navares-Gómez M, Mejía G, Román M, Koller D, Soria-Chacartegui P, Almenara S, Abad-Santos F. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Adv Ther 2020;37:3537-50. [PMID: 32564268 DOI: 10.1007/s12325-020-01414-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, Zubiaur P, Wojnicz A, Abad-Santos F. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol 2018;123:474-85. [PMID: 29723928 DOI: 10.1111/bcpt.13031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
9 Zhang X, Xiang Q, Zhao X, Ma L, Cui Y. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis. J Clin Pharm Ther 2019;44:163-73. [DOI: 10.1111/jcpt.12780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. The Lancet Psychiatry 2019;6:418-26. [DOI: 10.1016/s2215-0366(19)30088-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 14.3] [Reference Citation Analysis]
11 Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Clin Pharmacokinet 2021. [PMID: 34125422 DOI: 10.1007/s40262-021-01041-x] [Reference Citation Analysis]
12 Zubiaur P, Soria-Chacartegui P, Koller D, Navares-Gómez M, Ochoa D, Almenara S, Saiz-Rodríguez M, Mejía-Abril G, Villapalos-García G, Román M, Martín-Vílchez S, Abad-Santos F. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother 2021;133:111087. [PMID: 33378980 DOI: 10.1016/j.biopha.2020.111087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kiss Á, Menus Á, Tóth K, Déri M, Sirok D, Gabri E, Belic A, Csukly G, Bitter I, Monostory K. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. Eur Arch Psychiatry Clin Neurosci 2020;270:71-82. [PMID: 30604050 DOI: 10.1007/s00406-018-0975-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
14 Villapalos-García G, Zubiaur P, Navares-Gómez M, Saiz-Rodríguez M, Mejía-Abril G, Martín-Vílchez S, Román M, Ochoa D, Abad-Santos F. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Front Pharmacol 2021;12:718281. [PMID: 34690761 DOI: 10.3389/fphar.2021.718281] [Reference Citation Analysis]
15 Koller D, Saiz-Rodríguez M, Zubiaur P, Ochoa D, Almenara S, Román M, Romero-Palacián D, de Miguel-Cáceres A, Martín S, Navares-Gómez M, Mejía G, Wojnicz A, Abad-Santos F. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol 2020;86:2051-62. [PMID: 32250470 DOI: 10.1111/bcp.14300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
16 Gil-Martins E, Barbosa DJ, Silva V, Remião F, Silva R. Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. Pharmacol Ther 2020;213:107554. [PMID: 32320731 DOI: 10.1016/j.pharmthera.2020.107554] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
17 Alvarez-Herrera S, Escamilla R, Medina-Contreras O, Saracco R, Flores Y, Hurtado-Alvarado G, Maldonado-García JL, Becerril-Villanueva E, Pérez-Sánchez G, Pavón L. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne) 2020;11:195. [PMID: 32373066 DOI: 10.3389/fendo.2020.00195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zubiaur P, Benedicto MD, Villapalos-García G, Navares-Gómez M, Mejía-Abril G, Román M, Martín-Vílchez S, Ochoa D, Abad-Santos F. SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. J Pers Med 2021;11:204. [PMID: 33805706 DOI: 10.3390/jpm11030204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Soria-Chacartegui P, Villapalos-García G, Zubiaur P, Abad-Santos F, Koller D. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Front Pharmacol 2021;12:711940. [PMID: 34335273 DOI: 10.3389/fphar.2021.711940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Barliana MI, Kusuma ASW, Insani WN, Alfian SD, Diantini A, Mutakin M, Rostinawati T, Herlambang H, Puspitasari IM, Suwantika AA, Abdulah R. Genetic variation of ABCB1 (rs1128503, rs1045642) and CYP2E1 rs3813867 with the duration of tuberculosis therapy: a pilot study among tuberculosis patients in Indonesia. BMC Res Notes 2021;14:295. [PMID: 34332626 DOI: 10.1186/s13104-021-05711-8] [Reference Citation Analysis]
21 Carrascal-Laso L, Franco-Martín MÁ, García-Berrocal MB, Marcos-Vadillo E, Sánchez-Iglesias S, Lorenzo C, Sánchez-Martín A, Ramos-Gallego I, García-Salgado MJ, Isidoro-García M. Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy. J Pers Med 2020;10:E289. [PMID: 33352925 DOI: 10.3390/jpm10040289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Geers LM, Pozhidaev IV, Ivanova SA, Freidin MB, Schmidt AF, Cohen D, Boiko AS, Paderina DZ, Fedorenko OY, Semke AV, Bokhan NA, Wilffert B, Kosterink JGW, Touw DJ, Loonen AJM. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. Br J Clin Pharmacol 2020;86:1827-35. [PMID: 32198935 DOI: 10.1111/bcp.14288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zubiaur P, Saiz-Rodríguez M, Koller D, Ovejero-Benito MC, Wojnicz A, Abad-Santos F. How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures? Pharmacogenomics 2018;19:1285-97. [PMID: 30334473 DOI: 10.2217/pgs-2018-0101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Toja-Camba FJ, Gesto-Antelo N, Maroñas O, Echarri Arrieta E, Zarra-Ferro I, González-Barcia M, Bandín-Vilar E, Mangas Sanjuan V, Facal F, Arrojo Romero M, Carracedo A, Mondelo-García C, Fernández-Ferreiro A. Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. Pharmaceutics 2021;13:935. [PMID: 34201784 DOI: 10.3390/pharmaceutics13070935] [Reference Citation Analysis]
25 Koller D, Belmonte C, Lubomirov R, Saiz-rodríguez M, Zubiaur P, Román M, Ochoa D, Carcas A, Wojnicz A, Abad-santos F. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. J Psychopharmacol 2018;32:1212-22. [DOI: 10.1177/0269881118798605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Carrascal-Laso L, Isidoro-García M, Ramos-Gallego I, Franco-Martín MA. Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders. J Clin Med 2021;10:4275. [PMID: 34575384 DOI: 10.3390/jcm10184275] [Reference Citation Analysis]
27 Koller D, Belmonte C, Saiz-Rodríguez M, Zubiaur P, Román M, Ochoa D, Abad-Santos F. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers. Basic Clin Pharmacol Toxicol 2020;126:236-46. [PMID: 31520576 DOI: 10.1111/bcpt.13323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]